Etiology, ethics, and outcomes of chronic kidney disease in neonates.

CONCLUSION: Congenital anomalies of the kidneys and urinary tract is the most common etiology in neonates with CKD. Chronic kidney disease in neonates is associated with high morbidity and mortality rates. PMID: 29619487 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research

Related Links:

Conclusions: This is the first Italian prospective study performed with a large cohort of CKD patients over a 3-year period. Considering the multifactorial burden of diseases associated with CKD patients, the need for greater attention to CKD and related disorders is paramount.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
Authors: Zuckerman R, Patel M, Costanzo EJ, Dounis H, Haj RA, Seyedali S, Asif A Abstract Hydralazine is a direct-acting vasodilator, which has been used in treatment for hypertension (HTN) since the 1950s. While it is well known to cause drug-induced lupus (DIL), recent reports are indicating the emergence of the drug-induced anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (DIV). Herein, we describe two patients (aged 57 and 87 years) who presented with severe acute kidney injury (AKI), proteinuria, and hematuria. Both were receiving hydralazine for the treatment of hypertension. ANCA serology wa...
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
Publication date: Available online 13 March 2018 Source:American Journal of Kidney Diseases Author(s): Yoshio N. Hall There is ongoing recognition that a wide array of social, economic, and environmental factors influence individuals’ opportunities to engage in health care and healthy behaviors. Despite spending $34 billion annually on the care of patients with end-stage renal disease, the American public and nephrology community remain remarkably complacent about addressing “upstream” factors that influence the prevention, progression, and treatment of chronic kidney diseases. Recently, a growing number...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
We present a 64-year-old Hispanic female with a history of hypertension who was referred for chronic kidney disease management. The review of her laboratory tests revealed a serum creatinine of 1.5 –1.8 mg/dL and microalbuminuria (in the presence of a bland urine sediment) in the past year. She denied any history of diabetes, rheumatologic disorders or exposure to intravenous contrast, nonsteroidal anti-inflammatory drugs, herbals, and heavy metals. Serological workup was negative. A renal b iopsy showed diffuse infiltration of glomerulus with pale eosinophilic material strongly positive for Congo red stain and a sim...
Source: Case Reports in Nephrology and Dialysis - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: CVRFs may be present in early CKD, even before the decline in GFR. Routine screening for CVRFs, along with timely intervention, may prevent the progression of CVD and mortality later in life. PMID: 28809621 [PubMed - in process]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
Current guidelines on hypertension treatment in chronic kidney disease (CKD) patients discourage combined angiotensin converting enzyme inhibitor (ACEi) and angiotensin II receptor blocker (ARB) use due to the risk of an increased kidney function decline. However, dual compared to single renin-angiotensin system (RAS) blockade may have more efficacy with regard to hypertension and proteinuria. Among incident pre-dialysis patients (CKD 4-5) we compared dual with no or single RAS blockade regarding kidney function decline, and risk of renal replacement therapy (RRT) or death.
Source: Journal of the American Society of Hypertension - Category: Cardiology Authors: Source Type: research
Abstract AIM: Chronic kidney disease (CKD) may be an etiologic cause of aging, hypertension, diabetes mellitus (DM), and metabolic syndrome. However, the influence of these cardiovascular risk factors and their combination on the development of CKD remains controversial. This retrospective study evaluated the influence of cardiovascular risk factors and their combination on the incidence of CKD during a 6-year follow-up period in middle-aged and older males. METHODS: The subjects were 303 males without a history of cardiovascular disease, stroke, renal dysfunction, or dialysis treatment. A biochemical analysi...
Source: Clinical and Experimental Hypertension - Category: Cardiology Authors: Tags: Clin Exp Hypertens Source Type: research
A 51-year-old woman with a history of hypertension, latent tuberculosis (TB) infection (treated with 9 months of isoniazid), a previous episode of idiopathic pancreatitis, and stage 5 chronic kidney disease secondary to primary focal segmental glomerulosclerosis (FSGS) presented for follow-up 1 week after peritoneal dialysis catheter insertion. Her FSGS was initially steroid responsive, but subsequently became refractory to treatment, and she had persistent nephrotic range proteinuria. On examination, she had mild soreness at her peritoneal catheter site and trace edema.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Nephrology Image Source Type: research
In this study, we found a low rate of preeclampsia in a low-to-moderate risk cohort, with an incidence of AKI and maternal mortality consistent with reported literature. PMID: 28352008 [PubMed - in process]
Source: Saudi Journal of Kidney Diseases and Transplantation - Category: Urology & Nephrology Authors: Tags: Saudi J Kidney Dis Transpl Source Type: research
This study will be a multicentred, prospective, double-blind, randomised parallel controlled trial for hypertensive CKD patients in China. Patients will be randomised to one of two treatment groups: a combination of benidipine 4–8 mg/day and fosinopril 20 mg/day; or a combination of HCTZ 12.5–25 mg/day and fosinopril 20 mg/day. Patients will be followed up for 24 months after a month's fosinopril run-in. There will be dose-titration after 1 and 2 months. The primary endpoint is changes in estimated glomerular filtration rate (eGFR) from baseline to month 24. Secondary endpoints inc...
Source: BMJ Open - Category: Journals (General) Authors: Tags: Open access, Medical management, Urology Protocol Source Type: research
More News: Chronic Kidney Disease | Dialysis | Epidemiology | Hypertension | Medical Ethics | Middle East Health | Perinatology & Neonatology | Proteinuria | Saudi Arabia Health | Study | Urology & Nephrology